All 12 Quarter Horses have been placed on the Steward's List meaning they cannot run in any licensed jurisdiction in North America until the adjudication process has been finalized. Both trainers were ...

Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

It also touts the non-FDA-approved Hims & Hers weight-loss drug as the supreme and affordable solution to America’s obesity ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

For Tammy Gusher Delgado, 56, the decision to join a clinical trial was clear. With a recent multiple sclerosis diagnosis and a clinical trial offering either the study drug or an approved ...

Despite a recently-agreed $7.4 billion settlement, the Sackler family has yet to fully account for its role in America's ...

Just in time for the return of children to school last week, federal health authorities advised of yet another shortage of a ...

Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US counterparts.